Inventor

Arnon Rosenthal

Inventor

Woodside, CA, US

Overview

1994–2021

Patent span

Human necessities

Primary field (CPC A)

Patents· 80 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary

C07KPeptides33%

A61KPreparations for medical, dental or toiletry purposes28%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations22%

A01KAnimal husbandry6%

G01NInvestigating or analysing materials by determining their chemical or physical properties6%

C12NMicroorganisms or enzymes3%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests1%

C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms0%

PatentTitleYear

11,084,875Anti-TREM2 antibodies and methods of use thereof2021 10,875,919Chimeric receptors and methods of use thereof2020 10,849,992Methods of screening for sortilin binding antagonists2020 10,800,844Anti-Siglec-9 antibodies and methods of use thereof2020 10,723,788Anti-complement factor C1q Fab fragments and uses thereof2020 10,711,062Anti-CD33 antibodies and methods of use thereof2020 10,676,525Anti-TREM2 antibodies and methods of use thereof2020 10,590,198Anti-siglec-7 antibodies and methods of use thereof2020 10,590,190Anti-complement factor C1q antibodies and uses thereof2020 10,428,150Anti-sortilin antibodies and methods of use thereof2019 10,329,343Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide2019 10,323,086Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same2019 10,316,081Humanized anti-complement factor C1Q antibodies2019 10,308,718Anti-sortilin antibodies and methods of use thereof2019 10,227,398Anti-complement factor C1q antibodies and uses thereof2019 10,087,255Anti-sortilin antibodies and methods of use thereof2018 9,890,210'Antagonist antibodies directed against calcitonin gene-related peptide'2018 9,890,211'Antagonist antibodies directed against calcitonin gene-related peptide'2018 9,884,907'Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide'2018 9,884,908'Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide'2018 9,708,394'Anti-complement factor C1q antibodies and uses thereof'2017 9,708,398'Anti-NGF antibodies and methods using same'2017 9,498,530'Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same'2016 9,365,648'Methods of using anti-CGRP antagonist antibodies'2016 9,346,881'Antagonist antibodies directed against calcitonin gene-related peptide and methods using same'2016 9,340,614'Antagonist antibodies directed against calcitonin gene-related peptide and methods using same'2016 9,340,610'Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same'2016 9,328,168'Methods of using anti-CGRP antagonist antibodies'2016 9,279,018'Antagonist antibodies directed against calcitonin gene-related peptide and methods using same'2016 9,266,951'Antagonist antibodies directed against calcitonin gene-related peptide and methods using same'2016 9,212,222'Anti-NGF antibodies and methods using same'2015 9,115,194'Antagonist antibodies directed against calcitonin gene-related peptide and methods using same'2015 8,734,802'Methods of treating vasomotor symptoms using antibodies'2014 8,597,649'Antagonist antibodies directed against calcitonin gene-related peptide and methods using same'2013 8,591,898'Treatment of interstitial cystitis'2013 8,586,045'Methods of using anti-CGRP antagonist antibodies'2013 8,540,990'Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same'2013 8,425,905'Antibodies directed against amyloid-beta peptide and methods using same'2013 8,398,978'Antibodies directed against amyloid-beta peptide and methods using same'2013 8,394,939'Nucleic acid encoding fused'2013 8,268,593'Polynucleotides encoding antibodies directed against amyloid-beta peptide'2012 8,088,384'Anti-NGF antibodies and methods using same'2012 8,007,794'Antagonist antibodies directed against calcitonin gene-related peptide and methods using same'2011 7,935,342'Methods for treating obesity by administering a trkB antagonist'2011 7,927,594'Antibodies directed against amyloid-beta peptide'2011 7,807,165'Antibodies directed against amyloid-beta peptide and methods using same'2010 7,785,588'Anti-neurturin receptor-A antibody compositions comprising cytokines or neurotrophic factors'2010 7,763,250'Antibodies directed against amyloid-beta peptide and nucleic acids encoding same'2010 7,691,606'Polynucleotides encoding GDNFRÎ±'2010 7,691,973'GFRÎ±3 polypeptides'2010 7,655,232'Anti-NGF antibodies and methods using same'2010 7,579,161'Assay methods for suppressor of fused modulation of hedgehog signaling'2009 7,569,364'Anti-NGF antibodies and methods using same'2009 7,544,659'Promotion of axonal regeneration'2009 7,449,616'Anti-NGF antibodies and methods using same'2008 7,312,319'Neurotrophic factor (NT-4) immunoassay systems'2007 7,259,245'Anti-fused antibodies'2007 7,144,996'Nucleic acid encoding human suppressor of fused'2006 7,105,484'GDNF receptorÎ±'2006 7,026,138'Polynucleotides encoding GFRÎ±3'2006 6,777,196'Neurturin receptor'2004 6,566,091'Neurotrophic factor'2003 6,531,579'Fused polypeptides'2003 6,506,728'Methods using a novel neurotrophic factor, NT-4'2003 6,504,007'GDNF receptor'2003 6,492,139'Vertebrate smoothened proteins'2002 6,451,977'Fused polypeptides'2002 6,407,216'Vertebrate smoothened antibodies'2002 6,372,453'Neurturin receptor'2002 6,342,348'Neurturin receptor'2002 6,277,820'Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells'2001 6,174,701'Neuronal factor'2001 6,136,958'Antibodies to vertebrate smoothened proteins'2000 6,037,320'Neurotrophic factor (NT-4)'2000 6,025,157'Neurturin receptor'2000 6,022,708'Fused'2000 5,990,281'Vertebrate smoothened proteins'1999 5,830,858'Neurotrophic factor'1998 5,702,906'Antibodies to neurotrophic factor-4 (NT-4)'1997 5,364,769'Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production'1994

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1994–2013Patents assigned to GENENTECH INC (31)· patent assignee history

1994–2007Based in Pacifica, CA, US· patent location history

2000–2013Based in Burlingame, CA, US· patent location history

2003Based in Burlingham, CA, US· patent location history

2006–2021Based in Woodside, CA, US· patent location history

2010–2019Patents assigned to RINAT NEUROSCIENCE CORP (15)· patent assignee history

2012–2015Patents assigned to ROSENTHAL ARNON (9)· patent assignee history

2013–2016Patents assigned to LABRYS BIOLOG INC (9)· patent assignee history

2018–2021Patents assigned to ALECTOR LLC (10)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
GENENTECH INC	31	1994–2013
RINAT NEUROSCIENCE CORP	15	2010–2019
ALECTOR LLC	10	2018–2021
LABRYS BIOLOG INC	9	2013–2016
ROSENTHAL ARNONself	9	2012–2015

Locations

Location	Patents	Span
Woodside, California, US	52	2006–2021
Burlingame, California, US	17	2000–2013
Pacifica, California, US	10	1994–2007
Burlingham, California, US	1	2003